# Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.

> **NCT07190053** · — · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- Enthesitis-related Arthritis (ERA)
- Juvenile Psoriatic Arthritis (JPsA)

## Interventions

- **OTHER:** Secukinumab

## Key facts

- **NCT ID:** NCT07190053
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12
- **Primary completion:** 2029-09-18
- **Final completion:** 2029-09-18
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07190053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07190053, "Long Term Treatment Strategies and Effectiveness of Secukinumab in Patient With JIA Subtypes of JPsA and ERA: Study From German BIKER Registry.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07190053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*